NY-IFF
IFF (NYSE:IFF) today announced it has qualified for the third consecutive year as a constituent of the Dow Jones Sustainability Indices (DJSI), a family of benchmarks widely regarded as one of the world’s leading tools for investors to integrate sustainability considerations into their portfolios to increase long-term shareholder value. Named to both the 2022 World Index and the North America Index, IFF is the only company in its industry to be included.
The S&P Global Corporate Sustainability Assessment (CSA) serves as the basis for the ESG scores that power the DJSI and its prestigious list of selected companies. IFF’s total CSA score places the Company among the top 10 percent of sustainability performers in the world, as assessed from among the 2,500 largest companies in the S&P Global Broad Market Index (BMI). Similarly, IFF ranks among the top 20 percent of the 600 largest companies in the S&P Global BMI in North America.
The distinction of achieving an annual place on the DJSI – and even increasing its score from the prior year – underscores IFF’s ongoing leadership position in environmental, social and governance (ESG) management, despite significantly increasing its size and complexity following the merger with DuPont’s Nutrition & Biosciences division in 2021. The Company’s CSA disclosures scored in 2022 were the first to reflect its post-merger performance and outcomes, including those based on an increase from nearly 14,000 employees to more than 24,000, and an expanded global footprint.
IFF was also recognized for leadership in corporate transparency and performance on climate change by global environmental non-profit CDP, securing a place on its 2022 ‘A List’ for climate change for the eighth consecutive year. Based on IFF’s post-merger data reported through CDP’s 2022 Climate Change questionnaire, IFF is one of a small number of companies out of nearly 15,000 scored that were named to the ‘A List’ for climate change, based on its actions to reduce emissions, mitigate climate risks and develop the low-carbon economy. IFF also received an “A-“ in CDP’s other two categories for action to protect water security risks and forests.
“We’re very proud to be recognized by S&P Global and CDP for our ESG excellence in 2022,” said Frank Clyburn, CEO, IFF. “We credit these achievements to the laser focus of our global team—striving to be the most sustainable company we can be—guided by our ambitious Do More Good Plan. We know we have more work to do in 2023 and beyond, but these external validations continue to inspire us and are a reminder that we’re heading in the right direction.”
IFF’s Do More Good Plan is a comprehensive ESG roadmap aligned with the Company’s purpose of applying science and creativity for a better world, organized by the four strategic focus areas of Sustainable Solutions, Climate & Planetary Health, Equity & Wellbeing and Transparency & Accountability.
The 2022 DJSI and CDP recognitions follow several other competitive ESG ratings IFF received during the year, including being:
- Awarded the 2022 EcoVadis Platinum sustainability rating for the second time, placing IFF among the top 1% of companies assessed;
- Named for the first time to the 2022 Bloomberg Gender Equality Index for its commitment to transparency and setting a new standard in gender-related data reporting; and
- Recertified for the second consecutive year by the Economic Dividends for Gender Equality (EDGE) at the Move level globally for its commitment to workplace diversity and intersectional issues.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005902/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
